Seeking Alpha

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

The last time I wrote about 4D Molecular Therapeutics, Inc. (FDMT), it was in a Seeking Alpha article entitled “4d Molecular Therapeutics: Several Value Inflection Points To Watch In 2024.” In this ...
Nasdaq

4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform

EMERYVILLE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene ...
Labroots

Unraveling Arbovirus Emergence: Insights into the Molecular Switch from Vector to Host

The COVID-19 pandemic is a dramatic reminder of the problems that viral zoonoses can cause worldwide. The rapid development of vaccines and antivirals against SARS-CoV-2 was only possible because the ...
Healio

Astellas, 4D Molecular Therapeutics enter license agreement for retinotopic vector

Please provide your email address to receive an email when new articles are posted on . Astellas has gained the rights to utilize 4DMT’s R100 vector to deliver its unique genetic payloads. Astellas is ...
The Scientist

Showcasing the Importance of Molecular Testing for Vector-Borne Diseases

The epidemiology of known vector-borne pathogens is changing as common vectors move to new locations. Scientists seek novel strategies for mitigating public health risks and healthcare system burdens.
WGNO

Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets

TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular ...